Epidemiology and economic burden of Lewy body dementia in the United States

References

• Coughlin DG, Hurtig HI, Irwin DJ. Pathological influences on clinical heterogeneity in Lewy body diseases. Mov Disord. 2020;35(1):5–19.
   PubMed Web of Science ®Google Scholar
• Galvin JE, Balasubramaniam M. Lewy body dementia: the under-recognized but common FOE. Cerebrum. 2013;2013(13):13.
   PubMedGoogle Scholar
• Gomperts SN. Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia. Continuum. 2016;22(2 Dementia):435–463.
   PubMedGoogle Scholar
• McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89(1):88–100.
   PubMed Web of Science ®Google Scholar
• Alzheimer's Association. Lewy Body Dementia. [cited 2021 July 26]. Available from: https://www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/lewy-body-dementia.
   Google Scholar
• Lewy Body Dementia Association. About LBD. [cited 2021 July 8]. Available from: https://www.lbda.org/about-lbd/.
   Google Scholar
• Eisai Co. Ltd. ARICEPT® approved in Japan as treatment for dementia with Lewy bodies [press release]. [cited 2021 July 20]. Available from: https://www.eisai.com/news/news201452.html.
   Google Scholar
• U.S. Food and Drug Administration. Exelon®: Highlights of prescribing information. [cited 2021 July 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022083lbl.pdf.
   Google Scholar
• European Medicines Agency. Rivastigmine Actavis. [cited 2021 July 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/rivastigmine-actavis.
   Google Scholar
• Taylor JP, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19(2):157–169.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wilson L, Kornak J, et al. The costs of dementia subtypes to California Medicare fee-for-service, 2015. Alzheimers Dement. 2019;15(7):899–906.
   PubMed Web of Science ®Google Scholar
• Patel B. Lewy body dementia (LBD) prevalence and cholinesterase inhibitor use in Florida (abstract 6-011). In Paper presented at: The 71st American Academy of Neurology Annual Meeting2019; Philadelphia, Pennsylvania.
   Google Scholar
• Savica R, Grossardt BR, Bower JH, et al. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 2013;70(11):1396–1402.
   PubMed Web of Science ®Google Scholar
• Goodman RA, Lochner KA, Thambisetty M, et al. Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013. Alzheimers Dement. 2017;13(1):28–37.
   PubMed Web of Science ®Google Scholar
• Petrova M, Mehrabian-Spasova S, Aarsland D, et al. Clinical and neuropsychological differences between mild Parkinson's disease dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord Extra. 2015;5(2):212–220.
   PubMedGoogle Scholar
• Smirnov DS, Galasko D, Edland SD, et al. Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. Neurology. 2020;94(20):e2076–e2087.
   PubMed Web of Science ®Google Scholar
• Aldridge GM, Birnschein A, Denburg NL, et al. Parkinson's disease dementia and dementia with Lewy bodies have similar neuropsychological profiles. Front Neurol. 2018;9(123):123.
   PubMed Web of Science ®Google Scholar
• Chandler J, Nair R, Biglan K, et al. Characteristics of Parkinson's disease in patients with and without cognitive impairment. J Parkinsons Dis. 2021;11(3):1381–1392.
   Google Scholar
• Murman DL, Kuo SB, Powell MC, Colenda CC. The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies. Neurology. 2003;61(7):944–949.
   PubMed Web of Science ®Google Scholar
• Espinosa R, Davis M, Johnson S, et al. Direct medical costs of dementia with Lewy bodies by disease complexity. J Am Med Dir Assoc. 2020;21(11):1696–1704 e1695.
   PubMed Web of Science ®Google Scholar
• De Lew N. Medicare: 35 years of service. Health Care Financ Rev. 2000;22(1):75–103.
   PubMedGoogle Scholar
• Chronic Conditions Warehouse (CCW) Medicare Enrollment Charts. 2021. [cited 2022 March 22]. Available from: https://www2.ccwdata.org/web/guest/medicare-charts/medicare-enrollment-charts.
   Google Scholar
• Rector TS, Wickstrom SL, Shah M, et al. Specificity and sensitivity of claims-based algorithms for identifying members of medicare + choice health plans that have chronic medical conditions. Health Serv Res. 2004;39(6 Pt 1):1839–1857.
   PubMed Web of Science ®Google Scholar
• Desai U, Kirson NY, Ye W, et al. Trends in health service use and potentially avoidable hospitalizations before Alzheimer's disease diagnosis: a matched, retrospective study of US Medicare beneficiaries. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2019;11(1):125–135.
   PubMedGoogle Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
   PubMed Web of Science ®Google Scholar
• United States Department of Labor: Bureau of Labor Statistics: Consumer Price Index—All Urban Consumers. Medical Care. https://data.bls.gov/timeseries/.
   Google Scholar
• Hurd MD, Martorell P, Delavande A, et al. Monetary costs of dementia in the United States. N Engl J Med. 2013;368(14):1326–1334.
   PubMed Web of Science ®Google Scholar
• Lin PJ, Zhong Y, Fillit HM, et al. Medicare expenditures of individuals with Alzheimer's disease and related dementias or mild cognitive impairment before and after diagnosis. J Am Geriatr Soc. 2016;64(8):1549–1557.
   PubMed Web of Science ®Google Scholar
• Hartman M, Martin AB, Washington B, et al. The national health expenditure accounts T. National health care spending in 2020: growth driven by federal spending in response to the COVID-19 pandemic. Health Aff. 2022;41(1):13–25.
   Google Scholar
• Hershey LA, Coleman-Jackson R. Pharmacological management of dementia with Lewy bodies. Drugs Aging. 2019;36(4):309–319.
   PubMed Web of Science ®Google Scholar